What medication can be administered to control the heart rate of a patient diagnosed with obstructed hypertrophic cardiomyopathy?

1. Wigle ED. Novel insights into the clinical manifestations and treatment of hypertrophic cardiomyopathy. Curr Opin Cardiol. 1995;3:299–305. [PubMed] [Google Scholar]

2. Maron BJ, Towbin JA, Thiene G, et al. American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemiology and Prevention. Circulation. 2006;113:1807–1816. [PubMed] [Google Scholar]

3. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–276. [PubMed] [Google Scholar]

4. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and theapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:201–211. [PubMed] [Google Scholar]

5. Maron BJ, Roberts WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation. 1979;59:689–706. [PubMed] [Google Scholar]

6. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998;98:2505–2508. [PubMed] [Google Scholar]

7. Dickstein K, Cohen-Solal A, Filippatos G, et al. European Society of Cardiology; Heart Failure Association of the ESC (HFA); European Society of Intensive Care Medicine (ESICM) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J. 2008;29:2388–2442. [PubMed] [Google Scholar]

8. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–2239. [PubMed] [Google Scholar]

9. Braunwald E, Wigle ED. Idiopathic hypertrophic subaortic stenosis. Chest. 1973;64:222–224. [PubMed] [Google Scholar]

10. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303. [PubMed] [Google Scholar]

11. Braunwald E, Lambrew CT, Rockoff SD, Ross J Jr, Morrow AG. Idiopathic hypertrophic subaortic stenosis. A description of the disease based upon an analysis of 64 patients. Circulation. 1964;30:3–119. [PubMed] [Google Scholar]

12. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:805–807. [PubMed] [Google Scholar]

13. Maron BJ. The electrocardiogram as diagnostic tool for hypertrophic cardiomyopathy: Revisited [editorial] Ann Noninvas Electrocardiol. 2001;6:277–279. [PMC free article] [PubMed] [Google Scholar]

14. Yamaguchi H, Ischimura T, Nishiyama S, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol. 1979;44:401–412. [PubMed] [Google Scholar]

15. Bacharova L, Estes EH. Electrocardiographic diagnosis of left ventricular hypertrophy: depolarization changes. J Electrocardiol. 2009;42:228–232. [PubMed] [Google Scholar]

16. Sedaghat D, Zakir RM, Choe J, Klapholz M, Saric M. Cardiac amyloidosis in a patient with multiple myeloma: a case report and review of literature. J Clin Ultrasound. 2009;37:179–184. [PubMed] [Google Scholar]

17. McLeod CJ, Ackerman MJ, Nishimura RA, Tajik AJ, Gersh BJ, Ommen SR. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol. 2009;54:229–233. [PubMed] [Google Scholar]

18. Abbasi AS, McAlpin RN, Eber LM, Pearce ML. Echocardiographic diagnosis of idiopathic hypertrophic cardiomyopathy without outflow obstruction. Circulation. 1972;46:897–904. [PubMed] [Google Scholar]

19. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents; European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003;24:1965–1991. [PubMed] [Google Scholar]

20. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll. 2008;51:1369–1374. [PubMed] [Google Scholar]

21. Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:242–249. [PubMed] [Google Scholar]

22. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044–2051. [PubMed] [Google Scholar]

23. Behr ER, Elliott P, McKenna WJ. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev. 2002;6:482–486. [PubMed] [Google Scholar]

24. Habib G, Hoen B, Tornos P, et al. The Task force on the Prevention, Diagnosis, and Treatment of infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and by the International Society of Chemotherapy (ISC) for Infection and Cancer. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009) Eur Heart J. 2009;30:2369–2413. [PubMed] [Google Scholar]

25. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212–2218. [PubMed] [Google Scholar]

e1. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart. 2002;87:169–176. [PMC free article] [PubMed] [Google Scholar]

e2. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988;11:147–153. [PubMed] [Google Scholar]

e3. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation. 1990;82:1995–2002. [PubMed] [Google Scholar]

e4. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342:1778–1785. [PubMed] [Google Scholar]

e5. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–373. [PubMed] [Google Scholar]

e6. Musat D, Sherrid MV. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment. Anadolu Kardiyol Derg. 2006;6:9–17. [PubMed] [Google Scholar]

e7. Lim DS, Lutucuta S, Bachireddy P. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789–791. [PMC free article] [PubMed] [Google Scholar]

e8. Patel R, Nagueh SF, Tsybouleva N. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001;104:317–324. [PMC free article] [PubMed] [Google Scholar]

e9. Patel R, Nemoto S, DeFreitas G. Spironolactone reverses myocyte diasarray and interstitial fibrosis in the cardiac troponin T transgenic mouse model of hypertrophic cardiomyopathy [abstract] J Am Coll Cardiol. 2002;39 [Google Scholar]

e10. Maron BJ, Olivotto I, Spirito P, et al. Edipemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858–864. [PubMed] [Google Scholar]

e11. Thompson D, Naqvi N, Juul S. Effects of propranolol on myocardial oxygen consumption, substrate extraction and hemodynamics in hypertrophic obstructive cardiomyopathy. Br Heart J. 1980;44:488–498. [PMC free article] [PubMed] [Google Scholar]

e12. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation. 1996;94:467–471. [PubMed] [Google Scholar]

e13. Smedira NG, Lytle BW, Lever HM, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85:127–133. [PubMed] [Google Scholar]

e14. Park MH, Gilligan DM, Bernardo NL, Topaz O. Symptomatic hypertrophic obstructive cardiomyopathy: the role of dual-chamber pacing. Angiology. 1999;50:87–94. [PubMed] [Google Scholar]

e15. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY) Circulation. 1999;99:2927–2933. [PubMed] [Google Scholar]

e16. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415–2421. [PubMed] [Google Scholar]

e17. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2000;21:704–707. [PubMed] [Google Scholar]

e18. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492–1496. [PubMed] [Google Scholar]

e19. Spirito P, Maron BJ. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999;33:1071–1075. [PubMed] [Google Scholar]

e20. Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstogers P, Neuhaus L, Seipel L, Horstkotte D. Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results oft he TASH-registry of the German Cardiac Society. Z Kardiol. 2004;93:23–31. [PubMed] [Google Scholar]

e21. Gietzen FH, Leudner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients. Heart. 2004;90:638–644. [PMC free article] [PubMed] [Google Scholar]

e22. Fernandes VL, Nielsen C, Nagueh SF, et al. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardiovasc Interv. 2008;1:561–570. [PubMed] [Google Scholar]

Which medication is used as a first line treatment of hypertrophic cardiomyopathy?

Which medication is indicated for a patient diagnosed with restrictive cardiomyopathy to block inappropriate sympathetic stimulation and tachycardia?

What do beta blockers do for hypertrophic cardiomyopathy?

What negative inotropic agent can be administered to a patient with obstructive hypertrophic cardiomyopathy?